• Mon, Jan. 9, 12:44 PM
    • Thinly traded micro cap Esperion Therapeutics (ESPR +1.7%) perks up on more than triple normal volume, albeit on turnover of only 716K shares, in response to the initiation of a global cardiovascular outcomes trial (CVOT) assessing the effects of bempedoic acid on the occurrence  of major CV events in patients with or at high risk of cardiovascular disease who are considered "statin intolerant."
    • The large-scale trial, called CLEAR, will enroll ~12,600 subjects across 600 sites in 30 countries and will run almost five years. The treatment duration will be 3.5 years. If all goes well, the company expects to file marketing applications in the U.S. and Europe by 2022.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL) which plays a key role in cholesterol and fatty acid synthesis.
    Mon, Jan. 9, 12:44 PM
  • Nov. 3, 2016, 4:44 PM
    Nov. 3, 2016, 4:44 PM
  • Oct. 13, 2016, 11:00 AM
    Oct. 13, 2016, 11:00 AM
  • Oct. 13, 2016, 10:42 AM
    • Esperion Therapeutics (ESPR +10.5%) perks up in early trading in response to its announcement that patients with hypercholesterolemia (elevated LDL-C) who are being treated with any dose of statins will be included in its Phase 3 development program for bempedoic acid. A pivotal trial, CLEAR LDL-C, should commence by year end with top-line results expected in mid-2018. If all goes well, regulatory submissions will follow in H1 2019.
    • Its decision was based on positive top-line results from its eight-week Phase 2 study of bempedoic acid added to atorvastatin (Pfizer's (PFE -0.9%) LIPITOR) which showed a 22% reduction in LDL-C from baseline compared to placebo (p=0.0028) against a background of atorvastatin in all subjects. The administration of bempedoic acid also produced a 35% reduction in C-reactive protein, a biomarker of cardiovascular disease-related inflammation.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL) which plays a key role in cholesterol and fatty acid synthesis.
    Oct. 13, 2016, 10:42 AM | 7 Comments
  • Sep. 20, 2016, 12:43 PM
    Sep. 20, 2016, 12:43 PM
  • Sep. 20, 2016, 11:01 AM
    Sep. 20, 2016, 11:01 AM | 1 Comment
  • Aug. 4, 2016, 4:41 PM
    • Esperion Therapeutics (NASDAQ:ESPR): Q2 EPS of -$0.62 beats by $0.16.
    • Cash and cash equivalents of $48.8M.
    • Press Release
    Aug. 4, 2016, 4:41 PM | 1 Comment
  • Jul. 8, 2016, 12:25 PM
    • Anthera Pharmaceuticals (NASDAQ:ANTH) initiated with Buy rating and $10 (180% upside) price target by H.C. Wainwright.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Overweight rating and $70 (31% upside) price target by Piper Jaffray.
    • Eiger Biopharmaceuticals (NASDAQ:EIGR) initiated with Outperform rating and $34 (85% upside) price target by Oppenheimer.
    • Intercept Pharmaceuticals (NASDAQ:ICPT) initiated with Sell rating and $58 (61% downside risk) price target by Cantor Fitzgerald.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Equal Weight rating and $48 (73% upside) price target by Barclays.
    • Kite Pharma (NASDAQ:KITE) initiated with Equal Weight rating and $58 (21% upside) price target by Barclays.
    • Endologix (NASDAQ:ELGX) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $16 (14% upside) from $11.50.
    • Achillion Pharmaceuticals (NASDAQ:ACHN) upgraded to Outperform from Market Perform with a $13 (42% upside) price target by JMP Securities.
    • Humana (NYSE:HUM) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $150 (8% downside risk) from $196.
    • Ilumina (NASDAQ:ILMN) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $110 (22% downside risk) from $130.
    • T2 Biosystems (NASDAQ:TTOO) downgraded to Sell from Buy by BTIG Research. Price target lowered to $4 (26% downside risk) from $12.
    • Juno Therapeutics (JUNO) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $39 (40% upside) from $63.
    • Depomed (NASDAQ:DEPO) downgraded to Neutral from Buy with $20 (6% upside) price target by UBS.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Hold from Buy by WallachBeth.
    Jul. 8, 2016, 12:25 PM | 4 Comments
  • Jul. 1, 2016, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    Jul. 1, 2016, 10:28 AM | 5 Comments
  • Jun. 29, 2016, 12:46 PM
    Jun. 29, 2016, 12:46 PM
  • Jun. 29, 2016, 11:10 AM
    Jun. 29, 2016, 11:10 AM
  • Jun. 29, 2016, 9:16 AM
    Jun. 29, 2016, 9:16 AM | 3 Comments
  • Jun. 28, 2016, 5:37 PM
    • Top gainers, as of 5.25 p.m.: FUEL +3.1%. FSM +3.5%. HMY +2.1%. GFI +1.9%. INO +1.7%.
    • Top losers, as of 5.25p.m.: ESPR -24.0%. ANTH -7.2%. NKE -6.6%. HTCH -6.5%.
    Jun. 28, 2016, 5:37 PM | 2 Comments
  • Jun. 28, 2016, 5:07 PM
    • Nano cap Esperion Therapeutics (NASDAQ:ESPR) had a ugly day today despite the market's up move. Shares slumped almost 20% on more than a 35% spike in volume as informed investors ran for the exits ahead of the company's press announcement released at 4:05 pm which updated investors on the clinical development and regulatory path for lead product candidate bempedoic acid, its candidate for lowering "bad" cholesterol in patients intolerant of statins.
    • The good news is that a global pivotal Phase 3 trial to assess safety and efficacy should commence in Q4 as will a cardiovascular outcomes study. Esperion says the study timelines will support a European marketing application in 2019 for patients with elevated LDL-C, including those intolerant of statins and one in 2022 for CV disease risk reduction in statin-intolerant patients.
    • The bad news is the FDA's refusal to clarify a regulatory pathway for the LDL-C indication citing potential changes in their view of LDL-C lowering as a surrogate endpoint and the possibility of a shift in the future standard-of-care for statin-intolerant patients with elevated LDL-C. According to the company, if, indeed, lowering LDL-C is no longer a surrogate endpoint for approval, it will still submit a New Drug Application (NDA) for a CV disease risk reduction claim by 2022, which means potential approval is at least six years away.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL), which plays a key role in cholesterol and fatty acid synthesis.
    • Update: Shares are down 24% after hours on robust volume.
    Jun. 28, 2016, 5:07 PM | 12 Comments
  • May 4, 2016, 8:12 AM
    • Esperion Therapeutics (NASDAQ:ESPR): Q1 EPS of -$0.65 beats by $0.09.
    • Cash and equivalents of $37.2M.
    May 4, 2016, 8:12 AM | 7 Comments
  • Jan. 13, 2016, 9:44 AM
    • Esperion Therapeutics (NASDAQ:ESPR) commences a global Phase 3 long-term safety and tolerability study, called ETC-1002-040, assessing bempedoic acid (ETC-1002) in patients with hyperlipidemia (excess fat in the blood) whose LDL-C (bad cholesterol) is not adequately controlled with low-to-moderate dose statins. Top-line results should be available in Q4 2017.
    • The randomized, multicenter, double-blind, placebo-controlled study will evaluate a daily dose of 180 mg of bempedoic acid versus placebo in 900 patients at high cardiovascular risk. The primary endpoint is the safety and tolerability over 52 weeks. Secondary endpoints will assess the effects of bempedoic acid on various lipid and cardiometabolic measurements.
    • The study marks the launch of the company's Phase 3 development program of bempedoic acid, called CLEAR, focused on statin-intolerant patients with uncontrolled LDL-C levels. Management will provide more details on CLEAR in Q2.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL), which plays a key role in cholesterol and fatty acid synthesis.
    Jan. 13, 2016, 9:44 AM